Gamma Medica Launches Be Certain Campaign to Educate Women on Dense Breast Tissue

SALEM, N.H.--(BUSINESS WIRE)--Gamma Medica, a leader in molecular breast imaging technology (MBI), announced today it has launched the Be Certain campaign, featuring a dedicated microsite as the cornerstone of an initiative to spread awareness on breast density. Today, about half of all women in the United States have dense breast tissue, making them four to five times¹ more likely to develop breast cancer. Traditional screening technology alone is not advanced enough to accurately detect cancerous tumors for these women who have a higher intrinsic risk of developing cancer during the course of their lifetime.

The goal of the campaign is to confront the 40,000 deaths annually at the hands of breast cancer by empowering women to be proactive about their breast health and consult their doctors to gain a better understanding of risks associated with dense breast tissue. The microsite provides patients with a one-stop educational resource with the most updated, accurate information for women with dense breast tissue, allowing them to Be Certain about their screening results and the latest clinical data on breast cancer.

With the Be Certain campaign, Gamma Medica aims to shift the public conversation on breast cancer awareness by educating patients, physicians, breast surgeons, radiologists and the industry about how MBI can increase detection rates by 400 percent² and offer other benefits when used as a supplemental screening tool to the traditional mammogram. Visitors will have access to accurate information and statistics, testimonials and patient stories.

“Here at Gamma Medica, our goal is to educate patients and providers about dense breast tissue and the challenges and limitations of today’s current standard of care to provide comprehensive and accurate cancer screening results that can be served with clinically, proven supplemental technology,” said Philip Croxford, CEO of Gamma Medica. “MBI is a reliable alternative that has proven to increase the detection of six more cancers missed by mammography in women with dense breast tissue. We believe all women should expect a personalized care plan for their own clinical situation and access to the latest information that will empower them to make the best-informed choice about their diagnostics and treatment plans. The Be Certain campaign is a major step forward in education about dense breast tissue with an informed and balanced approach that can be trusted as reliable and accurate.”

About Gamma Medica, Inc.
Gamma Medica, Inc. is a women’s health company focused on overcoming the limitations of anatomical imaging experienced by mammography and other screening modalities in the early detection of breast cancer. The company’s LumaGEM® MBI system is the first commercially available, FDA-cleared, fully solid-state digital imaging system utilizing dual-head Digital Direct Conversion Gamma Imaging™ (DDCGI™) technology for molecular breast imaging. With over 90 percent sensitivity and specificity, LumaGEM MBI has been shown to significantly improve cancer detection in women with dense breast tissue with fewer false positives relative to anatomical imaging technologies, such as MRI and whole breast ultrasound. ³ For more information visit, www.gammamedica.com.

^{1 Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 356(3):227-36, 2007.
2 Rhodes DJ, Hruska CB, Conners AL, et al. JOURNAL CLUB: Molecular Breast Imaging at Reduced Radiation Dose for Supplemental Screening in Mammographically Dense Breasts. American Journal of Roentgenology. 2015;204(2):241-251.
3 Rhodes DJ, Hruska CB, Conners AL, et al. JOURNAL CLUB: Molecular Breast Imaging at Reduced Radiation Dose for Supplemental Screening in Mammographically Dense Breasts. American Journal of Roentgenology. 2015;204(2):241-251.}